ETCAMAH® (camizestrant), FDA‑Approved for HR+, HER2- Advanced Breast Cancer with Emergent ESR1 Mutation, Available at Biologics by McKesson
Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by AstraZeneca as a limited distribution specialty pharmacy provider for ETCAMAH® (camizestrant).
MIMRYLO™ (rusfertide), FDA-Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Available at Biologics by McKesson
Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Takeda to be part of a limited network of a specialty pharmacy providers for MIMRYLO™ (rusfertide). This newly FDA-approved, first-in-class therapy is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV) and is administered via subcutaneous injection.
CAVHANZA™ (nilotinib) Orally Disintegrating Tablets, FDA-approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), available at Biologics by McKesson
Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Cycle Pharmaceuticals as a limited distribution specialty pharmacy provider for CAVHANZA™ (nilotinib) Orally Disintegrating Tablets.
Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for RASONQUE™(daraxonrasib)
Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Revolution Medicines as a specialty pharmacy provider for RASONQUE™ (daraxonrasib) within its distribution network.
VEPPANU™ (vepdegestrant), FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
– Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Rigel Pharmaceuticals as the hub and a limited distribution specialty pharmacy provider for VEPPANU™ (vepdegestrant).
Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for HERNEXEOS® (zongertinib tablets)
Effective July 13, Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner.
Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for PHYRAGO™
Effective July 7, Cycle Pharmaceuticals’ PHYRAGO™ (dasatinib) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner
DECNUPAZ™(pivekimab sunirine-pvzy), FDA‑Approved for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Exclusively Available at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for DECNUPAZ, an intravenous therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm.
ZYCUBO® (copper histidinate), First FDA-Approved Treatment for Patients with Menkes Disease, Exclusively Available at Biologics by McKesson in the United States
Biologics by McKesson became the exclusive specialty pharmacy provider for ZYCUBO, the first FDA-approved treatment for pediatric patients with Menkes disease.
Biologics by McKesson’s Pharmacy Elite™ Selected as Hub for Rigel Pharmaceuticals’ Tavalisse®, Gavreto® and Rezlidhia®
Biologics by McKesson’s Pharmacy Elite was selected as Rigel’s hub for Tavalisse, Gavreto, and Rezlidhia, supporting access services including benefits investigation, prior authorization, and financial assistance navigation.